Group Leaders

Gøril Berntzen, PhD, Nextera Group Lead Biology

Group leaders

Gøril Berntzen, PhD, Group Lead Discovery

Gøril is an experienced molecular immunologist with expertise in drug and target discovery by use of phage display technologies in several disease areas including autoimmunity and oncology. She received her PhD in Molecular Immunology from the University of Oslo in 2006 and has since gained experience working in academia and for immunotherapy companies, including Affitech. Gøril joined Nextera in 2013 and is leading the Discovery Group on phage display selection and screening campaigns in immunotherapy discovery programs.

Sebastian Berge-Seidl, PhD, Nextera Group Lead Molecular Biology


Sebastian Berge-Seidl, PhD, Group Lead Molecular Biology

Sebastian has over 15 years’ experience in the field of molecular biology across various scientific disciplines, including cancer biology, cardiovascular disease, and immunology, with additional experience in project management. He received his PhD in Cancer Biology from the University of Oslo in 2013. Sebastian joined Nextera in 2016 and is leading the Molecular Biology Group focusing on compound design and development of new technologies.

Terje Frigstad, MSc, Nextera Group Lead Biology

Terje Frigstad, MSc, Group Lead Cell Biology

Terje is an experienced immunologist with expertise in molecular cell biology within the fields of oncology and autoimmune diseases. He received his MSc in molecular immunology from the University of Oslo in 2006 and joined Nextera from academia in 2010. Terje is leading the Cell Biology group focusing on discovery and characterisation of lead compounds and development of new technologies.
mark Fife, PhD, Nextera Group Lead Preclinical

Mark Fife, PhD, Group Lead Preclinical

Mark is an experienced immunologist with expertise in preclinical safety and efficacy assessment of soluble immunotherapies for a range of disease areas, including oncology and infectious disease. He received his PhD in Immunology from the University of Manchester in 2017 and has since gained experience working for various immunotherapy companies in the UK, including Immunocore, and Norway. Mark is leading the Preclinical Group with a focus on the development of lead compounds towards the clinic.
The Nextera Team